LON:CEL Celadon Pharmaceuticals (CEL) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Celadon Pharmaceuticals Stock (LON:CEL) Get CEL alerts:Sign Up Key Stats Today's Range N/A50-Day Range 13.40▼ 13.4052-Week Range N/AVolumeN/AAverage Volume226,267 shsMarket Capitalization£8.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com Read More Receive CEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CEL Stock News HeadlinesCeladon Pharmaceuticals Passes AGM Resolutions and Plans DelistingJuly 1, 2025 | tipranks.comAIM WINNERS & LOSERS: Celadon jumps; Frasers eyes Revolution BeautyJune 9, 2025 | lse.co.ukToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 21 at 1:00 AM | Behind the Markets (Ad)Celadon Pharmaceuticals Faces Financial Uncertainty Amid Funding EffortsJune 6, 2025 | tipranks.comCeladon Pharmaceuticals faces potential administrationJune 1, 2025 | investing.comCeladon Pharmaceuticals Faces Financial Uncertainty Amid Funding ChallengesMay 30, 2025 | tipranks.comCeladon Pharmaceuticals Terminates Credit Facility Amid Strategic Financial AdjustmentsApril 8, 2025 | tipranks.comCeladon Pharmaceuticals Faces Financial Uncertainty Amid Funding DelaysMarch 31, 2025 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:CEL CIKN/A Webwww.celadonpharma.co.uk Phone44 20 3150 0252FaxN/AEmployees2,780Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (7.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.97 million Net Margins-9,520.00% Pretax MarginN/A Return on Equity-131.82% Return on Assets-34.40% Debt Debt-to-Equity Ratio149.37 Current Ratio2.62 Quick Ratio6.97 Sales & Book Value Annual Sales£123.38 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.05 Book ValueGBX 3.80 per share Price / BookN/AMiscellaneous Outstanding Shares61,329,971Free FloatN/AMarket Cap£8.22 million OptionableNot Optionable Beta-0.26 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (LON:CEL) was last updated on 8/6/2025 by MarketBeat.com Staff. From Our PartnersElon masterplan could turn $500 into half a millionJeff Brown called Tesla an AI company in 2018, when Wall Street said it was going bankrupt. The stock has been...Brownstone Research | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.